[Alpha Tau in GlobeNewswire] Alpha Tau appoints industry veteran Peter Melnyk as Chief Commercial Officer

JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company’s Board of Directors in order to assume the full-time position of Alpha Tau’s Chief Commercial Officer.

Read more here.